Ito et al. demonstrated that EPHB4-CAR-T cells, especially when administered intratumorally, showed significant tumor regression and T infiltration in both OSCC xenograft and patient-derived xenograft (PDX) models [32]. Here, EPHB4 is linked to neoplasm.